Boston Scientific (BSX)
(Delayed Data from NYSE)
$74.45 USD
+0.96 (1.31%)
Updated May 15, 2024 04:00 PM ET
After-Market: $74.43 -0.02 (-0.03%) 7:20 PM ET
2-Buy of 5 2
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$74.45 USD
+0.96 (1.31%)
Updated May 15, 2024 04:00 PM ET
After-Market: $74.43 -0.02 (-0.03%) 7:20 PM ET
2-Buy of 5 2
C Value D Growth C Momentum D VGM
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Company News For Feb 7, 2019
by Zacks Equity Research
Companies In The News are: CPRI,BSX,GM,SNAP
Bright Near-Term Outlook for Medical Instruments Industry
by Zacks Equity Research
Growing medical awareness and economic prosperity have been enhancing the uptake of medical instruments in the emerging economies.
Boston Scientific (BSX) Beats on Q4 Earnings, Margins Dip
by Zacks Equity Research
Boston Scientific (BSX) is leaving no stone unturned to strengthen its core businesses and invest in global markets, which accounted for the uptick in sales across all geographies.
Boston Scientific (BSX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 5.41% and 0.11%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Can Boston Scientific (BSX) Q4 Earnings Fuel Overall Growth?
by Zacks Equity Research
We are hopeful that Boston Scientific (BSX) will report a strong IC business globally in Q4, backed by an innovative portfolio and robust commercial teams.
Boston Scientific (BSX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VREX vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
VREX vs. BSX: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Boston Scientific, Southern, BNY, Schlumberger and Southwest
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Boston Scientific, Southern, BNY, Schlumberger and Southwest
Top Analyst Reports for Boston Scientific, Southern Company & BNY Mellon
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Boston Scientific (BSX), Southern Company (SO) and BNY Mellon (BK).
Boston Scientific Gains on Impressive Preliminary Q4 Results
by Zacks Equity Research
Boston Scientific's (BSX) solid top line is expected to be backed by growth across all segments and geographical regions in Q4.
Boston Scientific (BSX) to Buy Residual Shares of Millipede
by Zacks Equity Research
Boston Scientific's (BSX) buyout of the leftover stake in Millipede will integrate the latter's IRIS Transcatheter Annuloplasty Ring System in the Structural Heart portfolio of the former.
HRC or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HRC vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific (BSX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Boston Scientific (BSX) closed at $37.67 in the latest trading session, marking a +1.7% move from the prior day.
HRC or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HRC vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific (BSX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Boston Scientific (BSX) closed at $34.60 in the latest trading session, marking a +1.62% move from the prior day.
Boston Scientific's (BSX) $4.2B Buyout to Augment PI Business
by Zacks Equity Research
Boston Scientific (BSX) continues to expand on the back of its inorganic growth strategy. The latest takeover is expected to boost the PI business.
Edwards Lifesciences' CE Mark for SAPIEN 3 Boosts THVT Arm
by Zacks Equity Research
Latest CE Mark receipt is expected to fortify Edwards Lifesciences' (EW) position in Europe.
Boston Scientific (BSX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Boston Scientific (BSX) closed at $36.48, marking a +0.75% move from the previous day.
Boston Scientific (BSX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Boston Scientific (BSX) closed at $38.60, marking a +0.42% move from the previous day.
HRC vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRC vs. BSX: Which Stock Is the Better Value Option?
Q3 Earnings Mixed
by Zacks Equity Research
Q3 Earnings Mixed
Boston Scientific (BSX) Beats on Q3 Earnings, Misses Revenues
by Zacks Equity Research
Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q3.
Boston Scientific (BSX) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 2.94% and -0.58%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Q3 Earnings on Oct 24: BSX, ALGN & More
by Zacks Equity Research
Long-term potential of the Medical Products industry appears promising at the moment amid certain short-term geopolitical insecurities.
Should You Buy Boston Scientific (BSX) Ahead of Earnings?
by Zacks Equity Research
Boston Scientific (BSX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.